Skip to content

Randomized Controlled Trial of Group Prevention Coaching

Randomized Controlled Trial of Group Prevention Coaching

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01838226
Enrollment
401
Registered
2013-04-23
Start date
2014-08-29
Completion date
2019-04-30
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Chronic Disease, Prevention, cardiovascular disease

Brief summary

Prevention of cardiovascular disease is a primary focus of the Secretary's New Models of Care Transformational Initiative. However, prevention has been hard to accomplish. The VA is committed to using group visits to address a wide array of primary care problems. Coaching is a method to help Veterans set and reach health goals by helping them overcome barriers to behavior change. Coaching can be performed one-on-one or in groups. This study will test the effectiveness of a group prevention coaching (GPC) intervention in improving cardiovascular risk. GPCs will focus on changing a behavior of the patient's choice that is likely to lead to improvements in heart disease risk. The coach will adopt a problem-solving approach to helping Veterans make these improvements. The primary outcome will be change in 10-year risk of major cardiac event; the investigators will also assess improvements in food choice, physical activity and weight.

Detailed description

Cardiovascular (CV) event prevention (e.g., myocardial infarction, cerebrovascular accident) remains the single most important public health problem in the United States, and cardiovascular disease is a leading cause of death among VA users. Improving the provision of prevention services is a primary focus of the Secretary's New Models of Care Transformational Initiative. However, prevention has been challenging to achieve. Multifactorial behavioral interventions are effective in treating a number of chronic illnesses (e.g., hypertension, diabetes), but less is known about their ability to reduce risk among patients without a unifying chronic illness. Group visits are an efficient, effective strategy for delivering a multifactorial behavior change intervention; the VA is committed to the group visit strategy to address a wide array of primary care problems. Groups have been shown to be an effective means of improving a number of outcomes in a number of individual diseases, but, again, their role in cardiovascular prevention among patients without a single common illness is unknown. Coaching is a type of multi-factorial behavioral intervention that involves goal-setting, and working to overcome barriers to behavior change. Coaching can be performed one-on-one, but coaching interventions have been delivered in group settings. The investigators have shown, in a 150-subject RCT, that group coaching plus individualized telephone coaching reduces cardiovascular risk, but the population in that study was very different from typical VA users. The investigators propose a three-site, two-arm randomized trial measuring the effectiveness of a group prevention coaching (GPC) intervention in improving cardiovascular risk, compared to VA usual care. The study will be performed at the Durham, Buffalo, and Syracuse VAMCs. Each arm will have 200 patients; patients will be VA users without prior history of cardiovascular event, but with at least 5% risk of such an event, and with either inadequately controlled hypertension or dyslipidemia, or current smoking. The GPC intervention will focus on changing a behavior of the patient's choice that is likely to lead to improvements in cholesterol, blood pressure, or to smoking cessation. Behaviors that will be reinforced will include but not be limited to healthy eating, decreased caloric intake, increased physical activity, stress reduction, and participatory decision making with physicians. Barriers to these behaviors will be identified. The coach will adopt a problem-solving approach to overcoming the above barriers and reinforcing the above behaviors; problem-solving is a well-described framework for behavior change. The GPC coach/interventionist for will be either the facility's Health Behavior Coordinator (HBC) or a person hired for the research enterprise but trained and credentialed identically to an HBC. All outcomes will be obtained at baseline, 6, and 12 months after enrollment by blinded research personnel. The primary outcome will be change in 10-year risk of fatal coronary event or non-fatal MI 6 months after enrollment, as measured by Framingham Risk Score. Key secondary outcomes will include dietary content by Food Frequency Questionnaire, physical activity as measured by International Physical Activity Questionnaire, and weight. The investigators will also determine if group cohesion, as measured by the Group Dynamics Inventory, influences the effectiveness of GPC. The investigators well also assess whether time spent in contact with a coach influences the effectiveness, by database log-in timekeeping strategies.

Interventions

BEHAVIORALProblem Solving

A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A diagnosis of inadequately controlled hypertension, as defined by an outpatient ICD-9 code of 401.x and a most recent blood pressure with either systolic \> 140 mmHg or diastolic \> 90 mmHg * OR (2) inadequately controlled dyslipidemia, as defined by most recent total cholesterol \> 200 mg/dl or HDL cholesterol \< 35 mg/dl * OR (3) current smoking, which can be identified using the CPRS Health Factor tied to the smoking clinical reminder. * Medication-taking status for these illnesses is neither required nor excluded.

Exclusion criteria

* Subjects with very high risk of cardiovascular event, as determined by any personal history of coronary artery disease (CAD) or other major cardiovascular disease (ICD-9 code of 410-414, or 425-429) * cerebrovascular disease (code 433-438) * peripheral arterial disease (codes 440.x or 443.x)

Design outcomes

Primary

MeasureTime frameDescription
Risk of Fatal Coronary Event or Non-fatal MI6 monthsThe primary outcome will be 10-year risk of fatal coronary event or non-fatal MI 6 months after enrollment, as measured by Framingham Risk Score. Scores range from 0 - 100, as this is a percentage of risk. Higher scores are worse, as they represent higher risk.

Secondary

MeasureTime frameDescription
Patient Activation Measure6 monthsMeasure of self-efficacy. Scored from 0-100, with 100 being higher self-efficacy and a better outcome.
Risk of Fatal Coronary Event or Non-fatal MI12 monthThe primary outcome will be 10-year risk of fatal coronary event or non-fatal MI 12 months after enrollment, as measured by Framingham Risk Score. Scores range from 0 - 100, as this is a percentage of risk. Higher scores are worse, as they represent higher risk.

Countries

United States

Participant flow

Participants by arm

ArmCount
Group Prevention Clinics
A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
202
Treatment as Usual Control
Usual VA care
199
Total401

Baseline characteristics

CharacteristicGroup Prevention ClinicsTreatment as Usual ControlTotal
Age, Continuous62.9 years
STANDARD_DEVIATION 11.1
61.9 years
STANDARD_DEVIATION 9.2
62.4 years
STANDARD_DEVIATION 10.2
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants4 Participants11 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
195 Participants195 Participants390 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Framingham Risk Score28.9 percent risk of event
STANDARD_DEVIATION 15.2
29.5 percent risk of event
STANDARD_DEVIATION 17.2
29.2 percent risk of event
STANDARD_DEVIATION 16.2
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
60 Participants69 Participants129 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
12 Participants14 Participants26 Participants
Race (NIH/OMB)
White
130 Participants116 Participants246 Participants
Region of Enrollment
United States
202 Participants199 Participants401 Participants
Sex: Female, Male
Female
21 Participants19 Participants40 Participants
Sex: Female, Male
Male
181 Participants180 Participants361 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 2020 / 199
other
Total, other adverse events
0 / 2020 / 199
serious
Total, serious adverse events
1 / 2020 / 199

Outcome results

Primary

Risk of Fatal Coronary Event or Non-fatal MI

The primary outcome will be 10-year risk of fatal coronary event or non-fatal MI 6 months after enrollment, as measured by Framingham Risk Score. Scores range from 0 - 100, as this is a percentage of risk. Higher scores are worse, as they represent higher risk.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Group Prevention ClinicsRisk of Fatal Coronary Event or Non-fatal MI27.0 percent risk of major cv event in 10 yrsStandard Deviation 17.2
Treatment as Usual ControlRisk of Fatal Coronary Event or Non-fatal MI26.3 percent risk of major cv event in 10 yrsStandard Deviation 15.5
p-value: 0.595% CI: [-1.3, 2.8]Mixed Models Analysis
Secondary

Patient Activation Measure

Measure of self-efficacy. Scored from 0-100, with 100 being higher self-efficacy and a better outcome.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Group Prevention ClinicsPatient Activation Measure62.1 units on a scaleStandard Deviation 11.5
Treatment as Usual ControlPatient Activation Measure62.6 units on a scaleStandard Deviation 12.2
95% CI: [-1.3, 3.1]Mixed Models Analysis
Secondary

Risk of Fatal Coronary Event or Non-fatal MI

The primary outcome will be 10-year risk of fatal coronary event or non-fatal MI 12 months after enrollment, as measured by Framingham Risk Score. Scores range from 0 - 100, as this is a percentage of risk. Higher scores are worse, as they represent higher risk.

Time frame: 12 month

ArmMeasureValue (MEAN)Dispersion
Group Prevention ClinicsRisk of Fatal Coronary Event or Non-fatal MI25.7 percent risk of cv event in 10 yearsStandard Deviation 15.4
Treatment as Usual ControlRisk of Fatal Coronary Event or Non-fatal MI28.2 percent risk of cv event in 10 yearsStandard Deviation 16.8
95% CI: [-4.9, -0.2]

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026